DARE logo
Dare Bioscience, Inc.(DARE)
Closing price · checked 8:21 PM ETAbout this dataData status
$0.41▼-0.04 (-9.87%)
Extended:$0.42+0.01 (+2.36%)· 8:21 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →
DARE Dare Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology
0.41-0.04-9.87% · Nov 20, 4:00 PM ET
Volume173.2K
Avg Vol242.4K
Open0.44
High0.44
Low0.41
Prev0.45
Mkt Cap8.01M
P/ENM
52W L 0.41
3.78 52W H
Rel volume0.71x
52W position0%
From 52W high-89.22%
vs 50D avg-42.12%
vs 200D avg-72.55%
1W return-30.26%
1M return-37.49%
3M return-49.17%
YTD return-79.11%
1Y return-78.10%
Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.

In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Management
  • Jennifer Kiang
    Vice President of Corporate Affairs & Development
  • Mark Walters
    Vice President of Operations
  • MarDee J. Haring-Layton
    Chief Accounting Officer
  • Sabrina Martucci Johnson
    Chief Executive Officer, President, Principal Financial Officer, Secretary & Director
  • David Friend
    Chief Scientific Officer
Company info
HeadquartersSan Diego, CA, US
Employees23
IPO dateApr 10, 2014
IndustryBiotechnology
ExchangeNASDAQ
1-year price · full chart
3.442.641.841.040.240.41Nov 25Mar 26Jul 26Nov 26
Returns
1W-30.26%
1M-37.49%
3M-49.17%
YTD-79.11%
1Y-78.10%
Key stats
Mkt Cap8.01M
P/ENM
Fwd P/E BF 12MNM
EPS-0.69
Beta1.15
50D Avg0.70
200D Avg1.48
P/B3.42
P/S5.68
Fwd P/S BF 12M1.76
Fwd EV/EBITDA BF 12MNM
Fwd PEG BF 12MNM
ROE-452.0%
Next EarningsMar 25, 2027

Methodology: Bloomberg · Fwd ratios on BF 12M consensus (FMP)

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.